Tarlatamab in previously treated SCLC: extended OS follow-up from DeLLphi-304, featured in a Proffered Paper Session at #ESMO26.
Primary analysis: median OS 13.6 vs 8.3 months with chemotherapy (HR 0.60).
@Larvol @myESMO @OncoAlert